Population Impact & Efficiency of Benefit‐Targeted Versus Risk‐Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease by Pletcher, Mark J. et al.
Population Impact & Efficiency of Benefit-Targeted Versus
Risk-Targeted Statin Prescribing for Primary Prevention of
Cardiovascular Disease
Mark J. Pletcher, MD, MPH; Michael Pignone, MD, MPH; Jamie A. Jarmul, BS; Andrew E. Moran, MD, MPH; Eric Vittinghoff, PhD; Thomas
Newman, MD, MPH
Background-—Benefit-targeted statin prescribing may be superior to risk-targeted statin prescribing (the current standard), but the
impact and efficiency of this approach are unclear.
Methods and Results-—We analyzed the National Health and Nutrition Examination Survey (NHANES) using an open-source model
(the Prevention Impact and Efficiency Model) to compare targeting of statin therapy according to expected benefit (benefit-targeted)
versus baseline risk (risk-targeted) in terms of projected population-level impact and efficiency. Impact was defined as relative %
reduction in atherosclerotic cardiovascular disease in the US population for the given strategy compared to current statin treatment
patterns; and efficiency as the number needed to treat over 10 years (NNT10, average and maximum) to prevent each
atherosclerotic cardiovascular disease event. Benefit-targeted moderate-intensity statin therapy at a treatment threshold of 2.3%
expected 10-year absolute risk reduction could produce a 5.7% impact (95% confidence interval, 4.8–6.7). This is approximately
equivalent to the potential impact of risk-targeted therapy at a treatment threshold of 5% 10-year atherosclerotic cardiovascular
disease risk (5.6% impact [4.7–6.6]). Whereas the estimated maximum NNT10 is much improved for benefit-targeted versus risk-
targeted therapy at these equivalent-impact thresholds (43.5 vs 180), the average NNT10 is nearly equivalent (24.2 vs 24.6).
Reaching 10% impact (half the Healthy People 2020 impact objective, loosely defined) is theoretically possible with benefit-targeted
moderate-intensity statins of persons with expected absolute risk reduction >2.3% if we expand age eligibility and account for
treatment of all persons with diabetes mellitus or with low-density lipoprotein >190 mg/dL (impact=12.4%; average NNT10=23.0).
Conclusions-—Benefit-based targeting of statin therapy provides modest gains in efficiency over risk-based prescribing and could
theoretically help attain approximately half of the Healthy People 2020 impact goal with reasonable efficiency. ( J Am Heart Assoc.
2017;6:e004316. DOI: 10.1161/JAHA.116.004316.)
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S tatins are effective at reducing the incidence of cardio-vascular disease events.1 Current guidelines recommend
primary prevention with statins targeted according to a
person’s estimated 10-year risk of atherosclerotic cardiovas-
cular disease (ASCVD) events (myocardial infarction, fatal and
nonfatal stroke, or coronary heart disease death) with a
treatment threshold of 7.5%, such that statins are recom-
mended for all persons with 10-year risk >7.5%.2 Some have
proposed targeting therapy instead according to the expected
benefit from statins (measured by the absolute reduction in
risk of events expected from statin therapy).3 Whereas
baseline risk is a good marker for expected benefit, the
expected benefit may also depend on individual characteris-
tics that modify statin effectiveness (eg, a person with very
low baseline lipid levels might have moderately high baseline
ASCVD risk, but relatively low expected benefit from statins1).
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ORIGINAL RESEARCH
Benefit-targeted primary prevention with statins may there-
fore be more efficient than risk-targeted primary prevention.
It is unclear, however, how much a switch to benefit-
targeted statin therapy from risk-targeted statin therapy
would actually benefit the US population. A previous analysis
projected that switching from risk-targeted statin therapy with
a baseline risk treatment threshold of 7.5% to benefit-targeted
statin therapy with an expected absolute risk reduction (ARR)
treatment threshold of 2.3% could lead to treatment of an
additional 9.5 million Americans and prevent an additional
266 508 cardiovascular events over 10 years3; but an
equivalent impact could be obtained by simply lowering the
baseline risk treatment threshold and treating more lower-risk
people. Lowering the treatment threshold would reduce
prevention efficiency to some extent, but the degree is
unclear. A direct comparison of the efficiency of benefit-
targeted versus risk-targeted statin therapy at equivalent-
impact treatment thresholds has not yet been presented.
We used the open-source Prevention Impact and Efficiency
Model4 to illustrate and evaluate the impact-efficiency trade-
offs of risk-targeted versus benefit-targeted statin therapy.
We specifically evaluated efficiency of these strategies over a
range of equivalent-impact treatment thresholds, and com-
pared the efficiency gains from benefit-targeted statin therapy
with gains that might be expected from improved risk
prediction or from more-efficacious prevention (ie, higher-
intensity statin therapy), and put results in the context of the
Healthy People 2020 impact objective of reducing cardiovas-
cular disease deaths by 20%.5
Methods
Model Overview and General Approach
We used the Prevention Impact and Efficiency (PIE) Model to
compare statin prescribing targeted by baseline risk versus
expected benefit. The PIE Model is a microsimulation
modeling method and open-source implementation, pro-
grammed in Stata, that is designed to illustrate trade-offs
between impact and efficiency of targeted prevention inter-
ventions.4 The PIE Model estimates impact (in terms of
relative % reduction in disease events) and efficiency (in terms
of the number of persons needed to treat [NNT] to prevent
each event) by (1) estimating baseline risk for each National
Health and Nutrition Examination Survey (NHANES) partici-
pant (using measurements from NHANES and applying an
externally derived risk prediction algorithm); (2) estimating the
reduction in disease risk in each NHANES participant that
might be achieved from an intervention, and applying it to
participants who meet targeting criteria; (3) estimating overall
population average risk before and after targeted treatment
with the intervention to estimate relative % reduction in
disease (impact); and (4) estimating the average and
maximum NNT to prevent each disease event (efficiency).
We used PIE Model methods to analyze NHANES, a
nationally representative cross-sectional survey of the US
population, to produce estimates of impact and efficiency of
benefit-targeted and risk-targeted statin therapy. The model
implementation files used for this analysis, programmed in
Stata (version 13; StataCorp LP, College Station, TX), are
archived and publicly available on the website.4 Besides the
simple example on the GitHub website (“PIEModelTem-
plate_v1.0”), this analysis is the first published use of the
PIE Model.
Target Population and Study Sample
We defined our target population as US adults, and our study
sample as participants in the NHANES 2011–2012 fasting
laboratory testing subsample who were at least 20 years of
age. For our primary analysis, we used multiple imputation
(n=10 imputed data sets generated) to impute missing values
of key variables (2.6% of all required measurements are
imputed—see Table S1) so that all adults participating in the
NHANES fasting laboratory testing sample were included and
our estimates are generalizable to the US population.
Sampling weights provided with NHANES for use with the
fasting laboratory testing subsample were used in all analy-
ses. NHANES is publicly available, and our analysis is exempt
from institutional review board review.
Estimating Baseline 10-Year Risk of
Atherosclerotic Cardiovascular Disease
Our target condition for this analysis is cardiovascular disease
events. To estimate baseline risk of cardiovascular disease
events in all adult patients in the population (required for
calculation of population impact in terms of relative % reduction
in events), we combined information from several published
cardiovascular risk equations and used additional assumptions
regarding risk and intervention efficacy in statin users.
For persons without pre-existing cardiovascular disease,
we used the 2013 American College of Cardiology/American
Heart Association Guideline on the Assessment of Cardiovas-
cular Risk2 to estimate 10-year risk of ASCVD, defined as fatal
and nonfatal myocardial infarction and stroke, for black and
white men and women using age, sex, systolic blood pressure,
total and high-density lipoprotein (HDL) cholesterol, blood
pressure medication use, current smoking status, and
diabetes mellitus measurements. To estimate risk for
NHANES participants who were Hispanic, Asian, or another
race/ethnicity besides black or white, we used the parame-
ters designed for white men and women, as suggested by the
Guideline.2
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For persons reporting pre-existing cardiovascular disease
(“Has a doctor or other health professional ever told you that
you had” coronary heart disease, angina, heart attack, or
stroke), we used a Framingham Heart Study–based calculator
designed for calculation of 2-year risk of recurrent coronary
heart disease (myocardial infarction, coronary insufficiency,
angina pectoris, and sudden and nonsudden coronary death;
stroke is not included).6,7 We calculated 2-year risk with
current age and current risk factor levels and then recalcu-
lated risk every 2 years (assuming that age increases, but no
other risk factors change) in order to extrapolate risk to
10 years, and then assumed that this estimate was compa-
rable to the ASCVD risk calculator described above. This
imperfect assumption allows us to make population-level
impact estimates in terms of relative % reduction in events in
the US population.
These risk estimates assume no treatment with statin
therapy. In order to estimate baseline risk in a statin user, we
estimated pretreatment lipid levels, calculated risk estimates
(as above) using these estimated pretreatment values, and
then applied statin-associated relative risk reductions to these
pretreatment risk levels.1 For persons reporting current use of
Pravastatin, Lovastatin, Simvastatin, or Fluvastatin, we esti-
mated pretreatment lipid measurements assuming these
medications had effects on total cholesterol (27% reduction),
low-density lipoprotein (LDL) cholesterol (34% reduction) and
HDL cholesterol (5% increase)8; for persons reporting current
use of Atorvastatin, Rosuvastatin, or Pitavastatin, we assumed
these medications had larger effects on total cholesterol (37%
reduction), LDL cholesterol (48% reduction), and HDL choles-
terol (5% increase)8; see Table S2 for tabulation of statin users
in the NHANES target population.
Estimating Reduced Cardiovascular Risk With
Moderate-Intensity Statins
We modeled statin effectiveness using methods and assump-
tions developed by Thanassoulis et al.3 We defined moderate-
intensity statins as statin therapy that achieves an LDL
reduction of 40% in persons who were not already taking a
statin. We translated the effects of LDL-lowering from statins
into a reduced event risk by applying the ARR formulation
developed by Thanassoulis et al,3 which is derived from the
Cholesterol Treatment Trialists (CTT) meta-analysis that
demonstrated an interaction in statin efficacy by baseline
level of risk (formulas provided by Thanassoulis et al in their
online appendix1). We used this calculated value—the
expected ARR—both to estimate the reduction in risk from
statins for each NHANES participant treated with statins (for
both benefit- and risk-targeted therapy) as well as to target
that therapy (for benefit-targeted therapy only). The PIE Model
Stata code implementing calculation of the expected ARR is
archived and available on the website4; the critical steps are
described below:
1 lnRRthanassoulis=0.10821+0.12346*ln(baselinerisk)
(from Thanassoulis et al3)
2 RRthanassoulis=exp(lnRRthanassoulis) (RR per mmol/L
LDL reduction)
3 RR=RRthanassoulis^(LDLreduction in mmol/L) (Calculated
RR for given patient)
To focus our base-case analysis on comparison of risk-
targeting versus benefit-targeting of statins for primary
prevention, we did not apply statin therapy in persons with
previous cardiovascular disease or diabetes, or with LDL
≥190 mg/dL, because statins are indicated in these groups
regardless of risk or expected statin benefit.2 These persons
are effectively omitted from our analysis, except that they
figure into the overall impact calculation given that they are
still part of the US population.
Estimating Impact and Efficiency for Each
Treatment Threshold
We serially analyzed prevention impact and efficiency for a
range of potential thresholds in baseline risk, and in expected
ARR, above which statins might rationally be applied. To
estimate prevention impact (relative % reduction in events in the
population), we compared pre- to post-intervention population-
averaged cardiovascular risk (calculated using study weights)
(=1(Average_Riskpost-intervention/Average_Riskpre-intervention),
then multiplied by 100 and expressed as a %). To estimate
prevention efficiency, we estimated average and maximum
NNT over 10 years (NNT
10
) to match the time frame of our
risk estimates. To obtain an average NNT10 estimate, we
calculated the mean risk difference (RiskuntreatedRisktreated)
among individuals in the treated subset (using study weights)
for each strategy and then took the inverse of that mean. To
obtain a maximum NNT10, we identified the single treated
individual with the smallest risk difference and took the
inverse of that value.3 These calculations are standard for the
PIE Model.4
Although we focus analyses on point estimates, we also
report 95% CIs for key estimates to illustrate imprecision
resulting from both sampling error and multiple imputation.
We calculate point estimates by analyzing all 10 imputed data
sets together in 1 combined data set; the resulting combined
estimates are asymptotically equivalent to estimates obtained
from analyzing each imputed data set separately and then
averaging the results (the standard method of analyzing
multiple imputation data sets). To estimate CIs, we devised a
novel Monte Carlo simulation approach. We first looped
through each of the 10 imputed data sets individually,
obtaining 1000 bootstrap samples9 from each imputed data
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set by resampling NHANES primary sampling units within
strata. We then obtained key estimates in each simulated
data set (n=1091000=10 000 total runs per estimate) and
reported the 2.5th and 97.5th percentile values as the 95%
CIs for each result. This approach is necessary because,
although Stata supports multiple imputation, bootstrapping,
and complex survey data analysis, it does not support these
methods in combination. Note that this Monte Carlo simula-
tion method estimates error from sampling and imputation,
but it does not account for uncertainty in our assumptions.
We do not present CIs for maximum NNT10 because this value
is entirely dependent (defined by) a single outlier value in the
data set and does not represent a statistical estimate.
Comparing Strategies
Our primary comparison was between risk-targeted prescrib-
ing, defined as moderate-intensity statins prescribed accord-
ing to level of baseline risk, and benefit-targeted prescribing,
defined as moderate-intensity statins prescribed according to
level of expected ARR. Prevention impact-efficiency curves are
provided to illustrated the trade-offs, labeling thresholds of
7.5% for baseline risk (the 2013 Guideline2), 2.3% for
expected ARR (for comparison with previous analyses3), and
equivalent-impact thresholds.
For comparison and context, we present results relative to
a 10% impact goal, which is half of the Healthy People 2020
impact objective of reducing coronary heart disease deaths by
20%5 (loosely defined), assuming the other half should be
attained by smoking cessation, lifestyle modification, blood
pressure control, or other methods. We also present results
for: (1) a hypothetical perfect risk prediction algorithm (where
risk is 100% in the high-risk group and 0% in the low-risk
group, and there is only 1 logical treatment threshold); (2)
age-targeted prescribing (a less-accurate, but more easily
applied method of statin targeting); (3) benefit-targeted
prescribing using the average relative risk reduction across
baseline risk groups (0.75 per mmol/L LDL reduction for
primary prevention and 0.80 for secondary prevention; see
Figure 1 of published meta-analysis1) without the baseline
risk interaction modeled by Thanassoulis et al3; (4) high-
intensity statins (with 50% LDL reduction for comparability3);
and (5) overall impact and efficiency accounting for treatment
of all patients with diabetes mellitus, and LDL ≥190 mg/dL,
and with expanded age eligibility for targeted statin therapy to
include adults <40 and >75 years of age.
Results
NHANES 2011–2012 includes 9756 individual participants, of
whom 3239 participated in the fasting laboratory test
subsample; 2627 were adults aged ≥20 years and represent
our target population. Most participants had a complete set of
measurements for our analysis (n=2290). Participants who
were missing 1 or more required measurements had higher
systolic blood pressure (P=0.023), higher total cholesterol
(P=0.002), lower HDL (P=0.001), and were more likely to be
diabetic (P=0.001; Table S1). With multiple imputation
(creating a 10-fold imputed data set with total
N=1092627=26 270; see Methods), we identified 7931
observations of persons eligible for targeted primary preven-
tion with statin therapy (ie, aged 40–75, no previous
cardiovascular disease or diabetes mellitus, not already on a
statin, and with LDL <190 mg/dL), representing 34% of the
US population (applying NHANES sample weights).
Among US adults eligible for targeted primary prevention
with statins (Table 1), Expected ARR was correlated with LDL
(r=0.34) and strongly correlated with baseline risk (r=0.93;
Figure 1). We estimate that 4% of the US adult population (11%
of the potentially eligible US population=8.4 million persons)
would be reclassified from statin not indicated to indicated
(expected ARR >2.3%) by switching from risk-targeted pre-
scribing at Guideline-suggested threshold (baseline risk
>7.5%2) to benefit-targeted prescribing at the recently sug-
gested expected ARR threshold (expected ARR >2.3%3). Only
0.03% of the US adult population (0.1% of the potentially
eligible US population=30 observations in the 10-fold multiple
imputation data set=3 NHANES participants) were reclassified
from statin indicated to not indicated (Figure 1; Table 1).
Figure 1. Estimated 10-year atherosclerotic cardiovascular dis-
ease (ASCVD) baseline risk and expected absolute risk reduction
(ARR) with moderate-intensity statins. Expected ARR is correlated
with baseline low-density lipoprotein (LDL; r=0.34) and baseline
risk (r=0.93). The solid reference line indicates the current standard
treatment threshold (baseline risk >7.5%); the dashed reference
lines indicate a proposed alternative (expected ARR >2.3%) and a
risk-targeted treatment threshold with approximately equivalent
impact (baseline risk >5%, see Figure 2).
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Compared with current treatment patterns, we estimate
that benefit-targeted prescribing of moderate-intensity statins
at an expected ARR threshold of 2.3% would reduce ASCVD
events in the US population by 5.7% (95% CI, 4.8–6.7%), at an
average NNT10 of 24.2 (23.1–25.4). In contrast, the impact of
risk-targeted prescribing of moderate-intensity statins at a
baseline risk threshold of 7.5% in the same population is
smaller—4.4% (3.7–5.2%)—but the average NNT10 is also
lower—21.2 (20.4–22.0), indicating better average preven-
tion efficiency (Table 2).
A more-direct comparison of prevention efficiency for
different targeting strategies can be attained by choosing
equivalent-impact thresholds. To match the impact of benefit-
targeting at a threshold of 2.3%, we can lower the risk-
targeting threshold to 5% (Figure 2), which would produce
5.6% impact (4.7–6.6%). At this threshold, the average NNT10
is nearly equivalent—24.6 (23.5–25.8; compare with 24.2 as
above)—though the maximum NNT10 becomes much higher
—180 (compare with 43.5; Table 2).
The impact-efficiency trade-off for these strategies can be
illustrated by plotting impact versus NNT10 (Figure 2). For any
given level of impact, the maximum NNT10 is substantially
lower for benefit-targeted prescribing than risk-targeted
prescribing (in Figure 2A, the green curve is shifted toward
the upper left corner compared with the red curve). The
average NNT10, however, is nearly identical (Figure 2B). For
comparison, we have plotted age-targeted prescribing of
moderate-intensity statins, which is substantially less efficient
by any metric; and benefit-targeted high-intensity statins,
which is substantially more efficient and also potentially more
Table 1. Characteristics of US Adults Aged 40 to 75 and Eligible for Targeted Primary Prevention With Statin Therapy*, by
Baseline 10-Year ASCVD Risk and Expected ARR From Moderate-Intensity Statins
Characteristic
Baseline Risk† <7.5% Baseline Risk† >7.5%
Expected ARR† <2.3% Expected ARR† >2.3% Expected ARR† <2.3% Expected ARR† >2.3%
N in US population‡, in millions 49.3 8.4 0.07 17.8
% of US population§ 22 4 0.03 8
Baseline risk†, %
Min to Max 0.06 to 7.2 3.9 to 7.5 7.5 to 8.4 7.5 to 35
Median (interquartile range) 1.5 (0.9–2.9) 6.2 (5.1–6.9) 8.4 (7.5–8.4) 11 (9.4–16)
Expected ARR, %
Min to Max 0.5 to 2.3 2.3 to 4.1 1.85 to 1.95 2.3 to 9.2
Median (interquartile range) 0.8 (0.5–1.4) 2.7 (2.5–3.1) 1.9 (1.85–1.95) 4.4 (3.7–5.3)
Age, mean yearsSD 486 567 572 628
Sex, % male 35 45 100 72
Systolic blood pressure†, mean mm HgSD 11813 12721 1266 13117
Total cholesterol, mean mg/dLSD 20034 22332 1396 21331
LDL cholesterol, current*, mean mg/dLSD 12030 14124 641.0 13028
HDL cholesterol, mean mg/dLSD 5615 5416 5412 5216
Smoking, % current 12 34 0 31
Current blood pressure medication use, % 17 24 61 49
Diabetes mellitus*, % 0 0 0 0
Current statin use*, % 0 0 0 0
Prevalent ASCVD*, % 0 0 0 0
ARR indicates absolute risk reduction; ASCVD, atherosclerotic cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Max, maximum; Min, minimum; NHANES,
National Health and Nutrition Examination Survey; Statin, HMG Co-A reductase inhibitor.
*NHANES participants younger than 40 years, older than 75 years, with LDL ≥190 mg/dL, with diabetes mellitus, with previous cardiovascular disease, or already on a statin are excluded
from this analysis.
†Baseline risk is defined as 10-year risk of ASCVD, estimated according to the 2013 Guideline2; expected ARR is the expected absolute risk reduction from moderate-intensity statin
therapy, as formulated by Thanassoulis et al3; see Methods.
‡US population estimates are calculated from the Ns in NHANES. Ns for columns 1 to 4 in the 10-fold imputed data set were 4725, 879, 30, and 2297, respectively; these Ns were divided
by 10 to correct for the 10-fold imputation and then multiplied by the sample weights provided by NHANES.
§US population % estimates use US population estimates‡ as the numerator, and all US adults in the denominator, such that the total % adds up to 34% (total % eligible for targeted primary
prevention*) rather than 100%. Note: All subsequent results describe only eligible persons* and use this as the denominator (so that %s add up to 100%) and are also weighted using
sample weights.
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impactful. For example, we project that high-intensity statins
prescribed for all persons with an expected ARR ≥2.3 would
produce a 7.1% (6.0–8.4) impact at an average NNT10 of 21.6
(20.7–22.6) and a maximum NNT10 of 43.3. Although
improved risk prediction will improve efficiency of targeted
therapy, it will not improve potential maximum impact for any
given strategy; for example, moderate-intensity statins with
even theoretical perfect prediction does not match the
potential impact of high-intensity statins prescribed for
persons with expected ARR ≥1.5 (expected impact=8.4%
[7.1–9.8] and average NNT10=26.3 [24.9–27.8]; Figure 2).
If our goal were to reduce cardiovascular disease by 10%
with statins alone (half of the Healthy People 2020 impact
objective of reducing coronary heart disease deaths by 20%,
loosely defined), targeted statin prescribing as defined here
would fall short (Figure 2). If we wanted to maximize impact,
but keep maximum NNT10 <50 (equivalent to targeting at
expected ARR >2.0%), we could achieve impact of 7.7% with
high-intensity statins (Figure 2). Even a treat-all approach with
high-intensity statins (which has a very high NNT10—
average=41.1, maximum [max]=1900) would achieve an
impact of only 9.7%. However, if we additionally account for
treatment of all persons with diabetes mellitus and LDL
>190 mg/dL, and allow treatment of persons of any age with
expected ARR >2.3, we could theoretically achieve an impact
of 12.4% with benefit-targeted moderate-intensity statins or
15.3% with high-intensity statins (Figure S1).
Sensitivity analyses demonstrate critical dependence of
our absolute impact and efficiency estimates on the
assumption that statins are relatively more effective (eg,
the relative risk reduction from statins, per mg/dL reduction
in LDL, is larger) in patients with lower baseline risk1 (see
Methods). When we substitute the average relative risk per
mmol/L reduction in LDL for patients without vascular
disease reported by the CTT,1 primary prevention with
statins (either risk- or benefit-targeted) at any given
threshold is substantially less impactful and less efficient,
and the impact of 2.3% expected ARR treatment threshold is
more akin to a baseline risk treatment threshold of 7.5%
than 5% (Figure S2). Note that our finding of nearly identical
average NNT for risk- versus benefit-targeted statin therapy,
however, is robust.
Discussion
Risk-targeted statin therapy leads to treatment of some
individuals with a relatively low expected benefit from therapy
(attributed to low baseline LDL levels), and treatment of these
individuals is inefficient (ie, the maximum NNT10 is high).
Benefit-targeted statin therapy, in contrast, intrinsically max-
imizes efficiency and is a more-rational choice for guiding
clinical decisions. A switch to benefit-targeted statin therapy,
however, will provide only very small gains in average
prevention efficiency compared with risk-targeted statin
therapy at equivalent-impact treatment thresholds. More-
Table 2. Impact and Efficiency Estimates for Risk-Targeted
Versus Benefit-Targeted Prescribing of Moderate-Intensity
Statins
Targeting Strategy
Treatment Threshold
Impact Efficiency
Proportion
of ASCVD
Events
Preventable
% (95% CI*)
Average NNT10
(95% CI*)
Maximum
NNT10
†
Risk-based prescribing
Treat all 8.3 (7.2–9.5) 48.3 (45.1–52.0) 2100
Treat if baseline
risk‡ >3%
6.8 (5.7–7.9) 29.1 (27.9–30.3) 180
Treat if baseline
risk >5%
5.6 (4.7–6.6) 24.6 (23.5–25.8) 180
Treat if baseline
risk >7.5%
4.4 (3.7–5.2) 21.2 (20.4–22.0) 54
Treat if baseline
risk >10%
3.2 (2.6–3.7) 19.1 (18.3–19.9) 39
Treat if baseline
risk >15%
1.6 (1.2–2.0) 16.2 (15.4–16.9) 39
Benefit-based prescribing
Treat all 8.3 (7.2–9.5) 48.3 (45.1–52.0) 2100
Treat if expected
ARR‡ >1.0%
7.5 (6.4–8.7) 33.6 (31.9–35.4) 100
Treat if expected
ARR >1.5%
6.9 (5.8–8.0) 29.2 (27.8–30.7) 66.5
Treat if expected
ARR >2.3%
5.7 (4.8–6.7) 24.2 (23.1–25.4) 43.5
Treat if expected
ARR >3.0%
4.8 (4.0–5.7) 21.6 (21.0–22.2) 33.3
Treat if expected
ARR >4.0%
3.3 (2.7–4.0) 18.6 (18.0–19.1) 24.9
Treat if expected
ARR >5.0%
1.9 (1.5–2.3) 15.6 (15.0–16.2) 19.9
ASCVD indicates atherosclerotic cardiovascular disease; CIs, confidence intervals;
NNT10, number need to treat over 10 years to prevent 1 event.
*CIs presented here are the 2.5th and 97.5th percentiles of the distribution of estimates
derived from analyzing bootstrapped samples accounting for the complex National
Health and Nutrition Examination Survey survey design and multiple imputation
procedure.
†We do not present confidence intervals for maximum NNT10 because this value is
entirely dependent (defined by) a single outlier value in the data set and does not
represent a statistical estimate.
‡Atherosclerotic cardiovascular disease (ASCVD) risk was estimated using the algorithm
described in the 2013 American College of Cardiology/American Heart Association
Guideline on the Assessment of Cardiovascular Risk2 for persons without pre-existing
cardiovascular disease, or an alternate Framingham-based risk equation6,7 with
extrapolation to 10 years, for persons with and without pre-existing cardiovascular
disease, respectively.
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sizable gains in efficiency and/or impact are attainable with
improvements in risk prediction or with more efficacious
therapy (eg, high-intensity statins). A 10% impact (half of the
Healthy People 2020 impact objective, loosely interpreted) is
not achievable with targeted statins alone, but could theoret-
ically be achievable with expanded eligibility criteria and
accounting for treatment of all persons with diabetes mellitus
or LDL >190 mg/dL.
Figure 2. Prevention impact and efficiency of benefit- versus risk-targeted statin prescribing. Impact
(relative % reduction in ASCVD events) and number needed to treat (NNT) over 10 years to prevent each
ASCVD event (lower NNT is more efficient) are illustrated across treatment thresholds for moderate- and
high-intensity statins targeted by expected absolute risk reduction (ARR) (benefit-based targeting) and
targeted by age or by baseline risk (risk-based targeting) or by perfect prediction (theoretical only).
Efficiency is plotted for both the maximum NNT (A) and average NNT (B). Dashed lines indicate 5.7% impact
(equivalent to the impact of moderate-intensity statins at expected ARR >2.3%) and 10% impact (a potential
impact goal for statin prescribing that might help attain Healthy People 2020 objectives5). ASCVD indicates
atherosclerotic cardiovascular disease.
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Our results are consistent with previous analyses by
Thanassoulis et al,3 who proposed the benefit-targeting
approach, developed an expected ARR estimation algorithm3
using the interaction with baseline risk identified by the CTT,1
and estimated population-level impact of using benefit-
targeted moderate-intensity statins with an expected ARR
treatment threshold of 2.3% by analyzing NHANES. Our
analysis of NHANES, using identical assumptions and a similar
approach, augmented by multiple imputation for enhanced
generalizability to the US population, produced consistent
estimates. We extended these findings by providing CIs
estimated using Monte Carlo simulation that account for
multiple imputation and sampling error in NHANES, illustrat-
ing the impact-efficiency trade-offs at different treatment
thresholds; providing estimates of efficiency for equivalent-
impact treatment thresholds allowing for a more-direct
comparison of benefit- versus, risk-targeted therapy; demon-
strating theoretical impact in the context of the Healthy
People 2020 impact objectives; and providing open-source
code for our model. We invite readers with access to Stata to
download and modify model files to further explore these
issues4; a sample of the Stata code required to produce
prevention impact-efficiency trade-off curves for Figure 2A
and Figure S1 is provided in Data S1.
We found that the assumption made by Thanassoulis et al3
of an interaction between baseline risk and statin effective-
ness has important implications for estimating impact and
efficiency of statin therapy, and also for how to implement
benefit-targeted statin therapy. Unlike risk-based targeting,
benefit-based targeting would use estimated expected ARR for
clinical decision making about statin treatment for individual
patients, and the expected ARR is very sensitive to the
interaction assumption. Thanassoulis et al3 did not evaluate
impact with a no-interaction assumption. The interaction
assumption is justified by the presence of a statistically
significant interaction detected by the CTT1 (P=0.003; see
Figure 21); however, that analysis starts with an assumption
that the effectiveness of statins scales with the degree of LDL
reduction1 (the relative risk from statin use is provided per
1 mmol/L LDL reduction), which is, in turn, dependent on the
baseline LDL level.8 This assumption has been controversial,
with some arguing that the effectiveness of statins varies only
by statin characteristics (potency) and not patient character-
istics (baseline LDL level),10 a position supported by recent
evidence.11 Indeed, current guidelines do not recommend
consideration of baseline LDL level in statin decision making
unless it is extremely high (>190 mg/dL).1 Our analysis
demonstrates the urgency of resolving this fundamental
question about statin effectiveness, especially if a benefit-
based approach to statin prescribing is to be implemented.
Our approach has some limitations. Our estimates assume
perfect implementation by clinicians and perfect acceptance
and adherence by patients and are thus only theoretically
attainable. The estimates are only as good as our assumptions
(eg, risk prediction and statin effectiveness estimates), and
our 95% CIs account only for random sampling and imputation
error and not for uncertainty in the assumptions themselves
(eg, statin efficacy); we have not attempted to evaluate these
sources of uncertainty, and our projections should be
considered dependent on the accuracy of these assumptions.
Alternate assumptions would be easy to evaluate by modifying
the open-source implementation files archived on the PIE
Model website.4 Unlike Thanassoulis et al,3 we have not
attempted to evaluate or incorporate a trials-based approach
to selecting patients and targeting statin therapy, and we have
made the assumption that statin effectiveness (modeled by
the algorithm proposed by Thanassoulis et al3) is uniform
across the population and independent of medical condition,
age, C-reactive protein levels,12 or other factors. The 10%
impact goal we use as a benchmark in our analyses is
relevant, but not equivalent, to (half of) the Healthy People
2020 objective of reducing coronary heart disease deaths by
20%,5 given that deaths may be reduced by a different
proportion than total ASCVD events. Our modeling approach
uses a simple fixed horizon at 10 years and does not attempt
to model downstream events after the occurrence of an
ASCVD event (or even to distinguish fatal from nonfatal
ASCVD events). Also, to obtain population-level impact
estimates, we needed to combine risk estimates from an
ASCVD risk calculator and a recurrent coronary heart disease
calculator, and make additional assumptions about detreat-
ing/retreating with statins. We do not attempt to model
adverse effects from statins or estimate cost or cost-
effectiveness. Finally, note that our impact and NNT estimates
are only relevant to the proposed use of statins under a given
policy (ie, treatment threshold) in comparison to current
treatment patterns; that is, the impact and efficiency of
prevalent statin use is used to define the baseline scenario,
excluded from the proposed intervention (because it has
already occurred), but accounted for when estimating impact
and efficiency of a proposed alternative scenario (because
prevalent statin users are still part of the US population
“denominator” for relative % reduction impact estimates).
Although benefit targeting of statin therapy produces only
very small average gains in efficiency compared to risk-
targeting at equivalent-impact treatment thresholds, benefit-
based targeting does limit treatment of some individuals with
a small expected benefit and is, in this sense, a more rational
approach to targeted prevention. In fact, it is the theoretical
ideal for maximizing targeted treatment efficiency for any
given targeted prevention therapy and provides an excellent
framework for rational translation of precision medicine
discoveries into gains in public health. Microsimulation
methods are naturally suited to modeling impact and
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efficiency of benefit-targeted precision medicine, and the PIE
Model, which uses these methods, may be generally useful for
helping translate precision medicine interventions into guide-
lines and policy. For statin therapy, the impact of benefit-
targeted therapy compared to risk-targeted therapy is small; it
is also highly dependent on our assumptions about how we
model statin efficacy, as described above. But benefit
targeting can help us apply evidence, when available, of
heterogeneity in statin effectiveness (eg, from biomarkers like
C-reactive protein12 or genetic testing13) that precision
medicine methods will help to generate. Before we can reap
these benefits, however, we will need more consensus and
updated guidelines that sanction this approach, as well as
clinician-friendly tools to calculate expected benefit similar to
what is now available for calculating baseline risk.14
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SUPPLEMENTAL MATERIAL
Data S1. Two snippets of the PIE Model configuration code used to define Figure 2a and Figure S1 
Intervention-Threshold pair labeling (for all Figures): 
* Choose and label the intervention-threshold pairs you want to graph (you can list ALL
POSSIBILITIES here, and decide later how to choose and order)
local pair1 `""Mod Statins, by Baseline Risk""'
local pair2 `""Mod Statins, by Expected ARR""'
local pair3 `""Mod Statins, by Age""'
local pair4 `""Mod Statins, perfect prediction""'
local pair5 `""High Statins, by Baseline Risk""'
local pair6 `""High Statins, by Expected ARR""'
local pair7 `""High Statins, by Age""'
local pair8 `""High Statins, perfect prediction""'
local pair9 `""Mod Statins with expanded elibigility, by Baseline Risk""'
local pair10 `""Mod Statins with expanded elibigility, by Expected ARR""'
local pair11 `""Mod Statins with expanded elibigility, by Age""'
local pair12 `""Mod Statins with expanded elibigility, perfect prediction""'
local pair13 `""High Statins with expanded elibigility, by Baseline Risk""'
local pair14 `""High Statins with expanded elibigility, by Expected ARR""'
local pair15 `""High Statins with expanded elibigility, by Age""'
local pair16 `""High Statins with expanded elibigility, perfect prediction""'
local pair17 `""Mod Statins without interaction, by Baseline Risk""'
local pair18 `""Mod Statins without interaction, by Expected ARR""'
local pair19 `""Mod Statins without interaction, by Age""'
local pair20 `""Mod Statins without interaction, perfect prediction""'
local pair21 `""Mod Statins if LDL>75, by Baseline Risk""'
local pair22 `""Mod Statins if LDL>75, by Expected ARR""'
local pair23 `""Mod Statins if LDL>75, by Age""'
local pair24 `""Mod Statins if LDL>75, perfect prediction""'
local pair25 `""Mod Statins with expanded eligibility, by Expected ARR""'
local pair26 `""High Statins with expanded eligibility, by Expected ARR""'
Configuration code for Figure 2a 
* Name the figure (no spaces allowed).
local figname "Figure2a"
* Choose NNT type: ave or max
local NNTtype "max" // "max" or "ave" 
* Name the events your model predicts; This will go into the axis label
local eventname "ASCVD"
* Referring to the pair numbers defined in the list above, choose which you want to show in this
figure
local pairs_included "3 1 2 6 4"      //
* For each threshold, specify where you want a threshold symbol marker.  Each will have an entry in
the legend if that threshold is chosen for display.
* Note: You don't need to specify the Treat All thresholds, nor the thresh0 markers.
* Note2: The symbol won't actually show up on the graph unless it is included in the
Dataset3_Results.dta dataset.  If you find you want a marker somewhere that isn't included in
Dataset3_Results.dta, adjust your Step3.do file so that result is generated.
local thresh1_label "Treat if Baseline Risk>="
local thresh1_symbols "5 7.5"
local thresh1_max = 20
local thresh2_label "Treat if Expected ARR-mod>=" 
local thresh2_symbols "2.3" 
local thresh2_max = 5 
local thresh3_label "Treat if Expected ARR-high>=" 
local thresh3_symbols "1.5 2.0 2.3" 
local thresh3_max = 5 
local thresh4_label "Treat if Age>=" 
local thresh4_symbols "50 60" 
local thresh4_max = 70 
Configuration code for Figure S1 
* Name the figure (no spaces allowed).
local figname "Figure_App1"
* Choose NNT type: ave or max
local NNTtype "ave" // "max" or "ave" 
* Name the events your model predicts; This will go into the axis label
local eventname "ASCVD"
* Referring to the pair numbers defined in the list above, choose which you want to show in this
figure
local pairs_included "2 6 25 26"
* For each threshold, specify where you want a threshold symbol marker.  Each will have an entry in
the legend if that threshold is chosen for display.
* Note: You don't need to specify the Treat All thresholds, nor the thresh0 markers.
* Note2: The symbol won't actually show up on the graph unless it is included in the
Dataset3_Results.dta dataset.  If you find you want a marker somewhere that isn't included in
Dataset3_Results.dta, adjust your Step3.do file so that result is generated.
local thresh2_label "Treat if Expected ARR-mod>="
local thresh2_symbols "2.3"
local thresh2_max = 5
local thresh3_label "Treat if Expected ARR-high>=" 
local thresh3_symbols "2.3" 
local thresh3_max = 5 
Table S1. Characteristics of NHANES 2011-2012 participants age≥20 years using sample weights, with and without multiple 
imputation 
Characteristic 
NHANES 
participants without 
missing risk factors  
(N= 2290) 
NHANES 
participants with one 
or more missing risk 
factors* 
(N= 337) p-value¶
US population 
estimates (using 
multiple imputation) 
(N=2627/sample‡) 
Age, mean years ± SD 47 ± 17 48 ± 15 .62 47 ± 17 
Sex, % male 48% 41% .12 48% 
Systolic blood pressure*, mean mmHg ± SD 121 ± 17 128 ± 18 .023 121 ± 17 
Total cholesterol, mean mg/dl ± SD 193 ± 40 212 ± 47 .002 194 ± 41 
LDL cholesterol, current†, mean mg/dl ± SD 115 ± 35 121 ± 36 .17 116 ± 35 
HDL cholesterol, mean mg/dl ± SD 54 ± 15 48 ± 17 .001 53 ± 15 
Smoking, % current 20% 16% .12 20% 
Diabetes, % 12% 23% .001 15% 
Current blood pressure medication use, % 29% 37% .10 30% 
Current statin use, % .040 
- None 81% 86% 81% 
- Standard dose¥ 13% 6% 
- High intensity¥ 6% 8% 
Prevalent ASCVD, % 8% 12% .19 
10-year ASCVD Risk†, median % (interquartile range) 2.4% (0.5% - 9.7%) ---* ---* 
Eligible for targeted primary prevention with statins€, % 35% ---* ---* 
Expected ARR from Moderate-Intensity Statins among US 
adults eligible for targeted primary prevention with 
statins€, median % (interquartile range) 
1.5% (0.7%-3.1%) ---* ---* 
13% 
6% 
8% 
2.5% (0.6% - 10%) 
34% 
1.5% (0.7%-3.1%) 
* - These participants are missing either systolic blood pressure (n=122), total cholesterol (n=187), LDL cholesterol (n=234), HDL cholesterol
(n=187), smoking status (n=4) or diabetes (n=1), and as such we cannot estimate 10-year ASCVD risk, eligibility for statins, or Expected ARR.  
Estimates provided for each risk factor exclude participants missing these values.  Two participants with missing systolic blood pressure were 
included in the first column because they had cardiovascular disease and therefore did not require a systolic blood pressure measurement for 
calculation of ASCVD risk3, 4.  Note that 2.6% of all measurements are imputed in the imputed datasets (= (122+187+234+187+4+1+2) / (2627 
persons*11 measurements)).  
¶ - p-values for comparison of participants with and without any missing values are calculated for each characteristic using sample weights multi-
stage sampling design variables, and include only those participants who are not missing that characteristic*. 
‡ - Number of observations in each of the 10 imputed datasets. 
† - Atherosclerotic cardiovascular disease (ASCVD) risk was estimated using the algorithm described in the 2013 ACC/AHA Guideline on the Assessment 
of Cardiovascular Risk5 for persons without pre-existing cardiovascular disease, or an alternate Framingham-based risk equation3, 4, with extrapolation to 10 
years for persons with and without pre-existing cardiovascular disease, respectively (see Methods).  Expected ARR for Moderate-Intensity Statin therapy 
was estimated using the formulation developed by Thanassoulis et al2, see Methods. 
¥ - We assumed persons reporting use of Pravastatin, Lovastatin, Simvastatin or Fluvastatin were using “Standard dose” statins and persons using
Atorvastatin, Rosuvastatin or Pitavastatin were using “High dose” statins. 
€ - NHANES participants age 40-75 years with LDL<190 mg/dl, no diabetes, no prior cardiovascular disease, and not already on a statin are eligible 
for targeted primary prevention with statin therapy. 
NHANES – National Health and Nutrition Examination Survey; SD – Standard deviation; LDL – Low-density lipoprotein; HDL – High-density 
lipoprotein; Statin – HMG Co-A Reductase Inhibitor; ARR – Absolute risk reduction 
Table S2. Assumed effects of different statins on total, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) cholesterol 
Statin 
Number of NHANES participants 
using the indicated statin 
Assumed effects* of the indicated statin on: 
Total cholesterol LDL cholesterol HDL cholesterol 
Pravastatin 60 -27% -34% +5%
Lovastatin 41 -27% -34% +5%
Simvastatin 244 -27% -34% +5%
Fluvastatin 0 -27% -34% +5%
Atorvastatin 105 -37% -48% +5%
Rosuvastatin 50 -37% -48% +5%
Pitavastatin 2 -37% -48% +5%
More than one statin 0 N/A N/A N/A 
None of the above† 2125 --- --- --- 
* - For persons reporting use the indicated statin, we assumed the statin caused reductions in total and LDL cholesterol and increases in HDL as
above (using Maron et al 2000; see Reference 8 in the main article), and used these assumptions to calculate pretreatment values for the purpose of 
risk estimation (see Methods). 
† - Total N for this analysis is the 2627 NHANES participants in our target population (see Methods).  
NHANES – National Health and Nutrition Examination Survey; LDL – Low-density lipoprotein; HDL – High-density lipoprotein 
Supplemental Figure Legends:
Figure S1.  Prevention Impact and Efficiency for Moderate-Intensity and High-Intensity Statins with and 
without expanded eligibility.  Impact (relative % reduction in ASCVD events) and number-needed-to-treat 
(NNT) over 10 years to prevent each ASCVD event (lower NNT is more efficient) are illustrated across 
treatment thresholds for moderate and high intensity statins targeted by expected absolute risk reduction 
(benefit-based prescribing) and either limited to persons age 40-75 years, LDL<190 mg/dl and without diabetes 
or prior cardiovascular disease (base-case analysis); or with expanded eligibility accounting for treatment of all 
persons with diabetes and LDL≥190 mg/dl, and treatment of all adults of any age meeting the given expected 
absolute risk reduction threshold.  Dashed line indicates 10% impact.  ASCVD – Atherosclerotic cardiovascular 
disease; LDL – Low-density lipoprotein cholesterol 
Figure S2.  Prevention Impact and Efficiency for Moderate-Intensity Statins with and without baseline 
risk interaction assumption.  Our base case analyses assume an interaction between Baseline Risk and statin 
effectiveness, as detected by the Cholesterol Treatment Trialists (CTT)1 and operationalized by Thansssoulis et 
al2 (see Methods).  This Figure demonstrates that impact and efficiency are both substantially less favorable for 
primary prevention with statins when an alternate assumption is used: that the overall average statin 
effectiveness estimate in the CTT meta-analysis (relative risk 0.75 per 1 mmol/L reduction in LDL from statins 
for primary prevention) applies to all persons.  
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